Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Clinical trial NCT05488548 · RECRUITING

Trial details

NCT number: NCT05488548
Sponsor: Epigenetix, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Castrate Resistant Prostate Cancer NUT Carcinoma Chronic Myelomonocytic Leukemia Myelofibrosis

Start date: 2022-12-21
Primary completion: 2025-05-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.